We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NVEC:NASDAQNVE Corporation Analysis

Data as of 2026-05-20 - not real-time

$83.49

Latest Price

8/10Risk

Risk Level: High

Executive Summary

NVE Corporation is trading at $83.49, comfortably above its 20‑day SMA of $85.86 and well above the 50‑day SMA of $77.43, indicating a short‑term bullish bias. However, the MACD histogram is negative (-1.16) and the signal line is bearish, while the RSI sits at a neutral 49, suggesting limited upside momentum. Volatility is elevated at 54% over the past 30 days and beta exceeds 1.5, pointing to a stock that can swing sharply on market moves. Fundamentally, the company appears significantly overvalued – the DCF‑derived fair value is only $28.50 versus the current price, and the PE of 26.6 is well below the industry average of 38.7, yet the price‑to‑book of 6.93 and price‑to‑sales of 15.34 remain high. The dividend yield of 4.88% looks attractive, but a payout ratio of 127% raises concerns about sustainability. Recent earnings showed a 27% jump in net income and management highlighted a shift toward defense sales in FY2027, providing a potential growth catalyst.
Overall, the stock’s technical setup is modestly bullish, but the valuation gap and dividend sustainability issues suggest caution, especially for investors seeking value or reliable income.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish price above short‑term moving averages
  • Negative MACD histogram indicating weakening momentum
  • Elevated short‑term volatility

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Significant overvaluation relative to DCF fair value
  • Unsustainable dividend payout ratio
  • High beta and sector risk in semiconductors

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential upside from defense sales expansion
  • Strong operating margins and cash generation
  • Continued valuation pressure limiting upside

Key Metrics & Analysis

Financial Health

Revenue Growth5.30%
Profit Margin57.72%
P/E Ratio26.6
ROE25.22%
ROA15.96%
Debt/Equity1.55
P/B Ratio6.9
Op. Cash Flow$16.7M
Free Cash Flow$7.3M
Industry P/E38.7

Technical Analysis

TrendBullish
RSI49.2
Support$75.00
Resistance$110.03
MA 20$85.86
MA 50$77.43
MA 200$69.25
MACDBearish
VolumeIncreasing
Fear & Greed Index90.02

Valuation

Fair Value$28.50
GradeOvervalued
TypeGrowth
Dividend Yield4.88%

Risk Assessment

Beta1.59
Volatility54.73%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.